A new analysis of Chantix (varenicline), from Pfizer, found no clinically or statistically significant increase in serious adverse cardiovascular events....
According to a study in the journal PLoS One, the poor safety profile of the Nicotine Addiction drug Chantix (varenicline),...
Pfizer announced the completion of a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of Chantix/Champix...
New FDA labeling for Chantix (varenicline) from Pfizer suggests that the anti-smoking medication may not carry the risks of suicidal...
Pfizer Inc. has announced that a new smoking-cessation clinical study assessing the efficacy and safety of varenicline (Chantix/Champix) met its...
Pfizer announced that the FDA approved updates to the Chantix (varenicline) labeling, including removal of the boxed warning regarding serious...
A joint meeting of the FDA Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee reviewed data from...
Achieve Life Sciences announced the successful topline results from the New Zealand RAUORA Phase III non-inferiority clinical trial comparing cytisinicline to Chantix (varenicline) in Maori (indigenous New Zealanders) and whanau (family) of Maori.
Pfizer Inc.has announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES...